Free Trial

Zacks Research Brokers Lower Earnings Estimates for BIO

Bio-Rad Laboratories logo with Medical background

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Analysts at Zacks Research dropped their Q2 2025 earnings estimates for shares of Bio-Rad Laboratories in a report issued on Thursday, July 10th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $1.93 for the quarter, down from their previous forecast of $2.03. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q4 2025 earnings at $2.57 EPS, FY2025 earnings at $9.23 EPS, Q1 2026 earnings at $2.79 EPS, Q3 2026 earnings at $2.49 EPS, Q4 2026 earnings at $2.78 EPS, FY2026 earnings at $10.52 EPS and Q1 2027 earnings at $2.45 EPS.

Several other equities analysts also recently issued reports on BIO. Wells Fargo & Company cut their price target on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating for the company in a report on Monday, June 9th. Royal Bank Of Canada cut their price target on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. UBS Group cut their price target on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Citigroup cut their price target on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, Wall Street Zen raised shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $324.25.

Check Out Our Latest Stock Report on BIO

Bio-Rad Laboratories Price Performance

BIO stock traded down $2.54 during trading on Friday, hitting $257.34. 298,849 shares of the stock traded hands, compared to its average volume of 346,735. Bio-Rad Laboratories has a one year low of $211.43 and a one year high of $387.99. The stock has a market cap of $7.00 billion, a price-to-earnings ratio of -3.38 and a beta of 0.95. The company has a 50 day simple moving average of $237.15 and a 200 day simple moving average of $269.16. The company has a current ratio of 5.99, a quick ratio of 4.43 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical research company reported $2.54 earnings per share for the quarter, beating the consensus estimate of $1.73 by $0.81. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. The business had revenue of $585.40 million for the quarter, compared to analyst estimates of $573.01 million. During the same period in the previous year, the business earned $2.30 EPS. The firm's revenue was down 4.2% on a year-over-year basis.

Hedge Funds Weigh In On Bio-Rad Laboratories

Institutional investors have recently modified their holdings of the stock. Signaturefd LLC grew its position in shares of Bio-Rad Laboratories by 13.2% during the 4th quarter. Signaturefd LLC now owns 265 shares of the medical research company's stock worth $87,000 after buying an additional 31 shares during the period. Thrivent Financial for Lutherans grew its position in shares of Bio-Rad Laboratories by 0.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company's stock worth $1,488,000 after buying an additional 32 shares during the period. Picton Mahoney Asset Management grew its position in shares of Bio-Rad Laboratories by 55.6% during the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after buying an additional 35 shares during the period. Lecap Asset Management Ltd. grew its position in shares of Bio-Rad Laboratories by 3.1% during the 1st quarter. Lecap Asset Management Ltd. now owns 1,600 shares of the medical research company's stock worth $390,000 after buying an additional 48 shares during the period. Finally, State of Alaska Department of Revenue grew its position in shares of Bio-Rad Laboratories by 2.5% during the 1st quarter. State of Alaska Department of Revenue now owns 2,254 shares of the medical research company's stock worth $548,000 after buying an additional 55 shares during the period. 65.24% of the stock is owned by institutional investors.

About Bio-Rad Laboratories

(Get Free Report)

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Featured Stories

Earnings History and Estimates for Bio-Rad Laboratories (NYSE:BIO)

Should You Invest $1,000 in Bio-Rad Laboratories Right Now?

Before you consider Bio-Rad Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.

While Bio-Rad Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines